Status:

ACTIVE_NOT_RECRUITING

Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study

Lead Sponsor:

Sanofi

Collaborating Sponsors:

Regeneron Pharmaceuticals

Conditions:

Prurigo Nodularis

Eligibility:

All Genders

18+ years

Brief Summary

This study is a prospective, multinational, observational investigation designed to elucidate the real-world effectiveness and treatment patterns of dupilumab therapy in adult patients diagnosed with ...

Detailed Description

The follow-up period will be 18 months or until death, loss to follow-up, or withdrawal, whichever comes first.

Eligibility Criteria

Inclusion

  • Patients aged 18 years or older at the time of informed consent.
  • Physician decision to treat the patient with dupilumab for prurigo nodularis (according to the country-specific prescribing information) made prior to and independently of the patient's participation in the study.
  • Patients able to understand and complete study-related questionnaires.
  • Patients provide voluntary informed consent to participate in the study before inclusion in the study.

Exclusion

  • Patients who have a contraindication to dupilumab according to the country-specific prescribing information label.
  • Any condition that, in the opinion of the Investigator, may interfere with the patient's ability to participate in the study, such as short life expectancy, substance abuse, severe cognitive impairment, or other comorbidities that can predictably prevent the patient from completing the schedule of visits and assessments.
  • Patients currently participating in any interventional clinical trial.
  • Prior use of dupilumab within 6 months of the screening visit, or within 6 months of the baseline visit if screening and baseline occur on the same day.

Key Trial Info

Start Date :

December 12 2023

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

September 22 2026

Estimated Enrollment :

100 Patients enrolled

Trial Details

Trial ID

NCT05991323

Start Date

December 12 2023

End Date

September 22 2026

Last Update

September 16 2025

Active Locations (49)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (49 locations)

1

Medical Dermatology Specialists Site Number : 8400005

Phoenix, Arizona, United States, 85006-2754

2

Saguaro Dermatology Associates, LLC - Probity - PPDS- Site Number : 8400024

Phoenix, Arizona, United States, 85008-3884

3

Center for Dermatology Clinical Research- Site Number : 8400002

Fremont, California, United States, 94538

4

Halcyon Dermatology- Site Number : 8400023

Laguna Hills, California, United States, 92653